<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918877</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000306</org_study_id>
    <nct_id>NCT02918877</nct_id>
  </id_info>
  <brief_title>Anesthetics to Prevent Lung Injury in Cardiac Surgery</brief_title>
  <acronym>APLICS</acronym>
  <official_title>Anesthetics to Prevent Lung Injury in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether the use of inhaled anesthetics, compared&#xD;
      to intravenous anesthetics, can affect the amount of lung inflammation and postoperative&#xD;
      respiratory complications seen after cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, controlled trial involving 45 adult patients undergoing cardiac surgery with&#xD;
      cardiopulmonary bypass. Patients will be randomized to receive either inhaled anesthesia with&#xD;
      sevoflurane or total intravenous anesthesia (TIVA) with propofol for the maintenance phase of&#xD;
      their cardiac anesthetic. Assessment of lung inflammation will take place using fiberoptic&#xD;
      bronchoscopic sampling of lung fluid as well as serum collection before and after exposure to&#xD;
      cardiopulmonary bypass, and the incidence of compositive postoperative pulmonary&#xD;
      complications will take place in the postoperative period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 24, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage (BAL) Concentration of TNF Alpha (pg/mL)</measure>
    <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
    <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Postoperative Pulmonary Complications</measure>
    <time_frame>Assessed daily, beginning on the first day after surgery, until hospital discharge or death. On average at our institution, most patients are discharged within 7 days so this is the expected time frame for follow up.</time_frame>
    <description>Composite endpoint of clinically relevant pulmonary complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAL Concentration of IL1b (pg/mL)</measure>
    <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
    <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAL Concentration of IL6 (pg/mL)</measure>
    <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
    <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAL Concentration of IL8 (pg/mL)</measure>
    <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
    <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAL Concentration of MCP1 (pg/mL)</measure>
    <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
    <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAL Concentration of sRAGE (pg/mL)</measure>
    <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
    <description>Biomarker of lung injury (RAGE - receptor for advance glycosylation end products)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Inflammatory Lung Injury</condition>
  <condition>Ischemia-Reperfusion Lung Injury</condition>
  <condition>Postoperative Pulmonary Complications</condition>
  <arm_group>
    <arm_group_label>Inhaled Anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Volatile Anesthetic</description>
    <arm_group_label>Inhaled Anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Intravenous Anesthetic</description>
    <arm_group_label>Intravenous Anesthesia</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (age 18+)&#xD;
&#xD;
          -  Undergoing cardiac surgery with cardiopulmonary bypass&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  History of severe COPD, emphysema, or ILD&#xD;
&#xD;
          -  Recent (&lt;2wk) or current use of systemic glucocorticoids&#xD;
&#xD;
          -  Prior history of pneumothorax&#xD;
&#xD;
          -  Allergy/contraindication to intravenous anesthetics&#xD;
&#xD;
          -  Personal or family history of malignant hyperthermia or high risk for malignant&#xD;
             hyperthermia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian O'Gara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <results_first_submitted>February 16, 2021</results_first_submitted>
  <results_first_submitted_qc>April 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2021</results_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Brian O'Gara</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Volatile Anesthetics</keyword>
  <keyword>Intravenous Anesthetics</keyword>
  <keyword>Inflammatory Lung Injury</keyword>
  <keyword>Postoperative Pulmonary Complications</keyword>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02918877/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>51 Enrolled</recruitment_details>
      <pre_assignment_details>49 Randomized&#xD;
Withdrew consent (1)&#xD;
Surgery cancelled (1)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Anesthesia</title>
          <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Anesthesia</title>
          <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery cancelled</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received intraoperative steroids</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to obtain lab samples</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsafe to perform BAL</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Anesthesia</title>
          <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Anesthesia</title>
          <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="10.1"/>
                    <measurement group_id="B2" value="64.6" spread="10.9"/>
                    <measurement group_id="B3" value="62.9" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207.82" spread="39.60"/>
                    <measurement group_id="B2" value="194.10" spread="42.54"/>
                    <measurement group_id="B3" value="200.96" spread="41.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.11" spread="3.65"/>
                    <measurement group_id="B2" value="68.41" spread="3.49"/>
                    <measurement group_id="B3" value="68.76" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.20" spread="4.34"/>
                    <measurement group_id="B2" value="29.61" spread="5.02"/>
                    <measurement group_id="B3" value="30.41" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obesity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Obstructive Pulmonary Disease/Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes without Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes with End Organ Damage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate or Severe Renal Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solid (Non-Metastatic) Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Score (American Society of Anesthesiologists)</title>
          <description>Higher scores indicate worse preoperative comorbidity burden (on a range of 1-6).</description>
          <units>scores on a scale.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.67" spread="0.48"/>
                    <measurement group_id="B2" value="3.82" spread="0.39"/>
                    <measurement group_id="B3" value="3.75" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ARISCAT Score</title>
          <description>Higher scores indicate worse predicted risk for postoperative pulmonary complications (range 0-123).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.28" spread="10.20"/>
                    <measurement group_id="B2" value="47.86" spread="8.15"/>
                    <measurement group_id="B3" value="49.07" spread="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage (BAL) Concentration of TNF Alpha (pg/mL)</title>
        <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
        <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Anesthesia</title>
            <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Anesthesia</title>
            <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL) Concentration of TNF Alpha (pg/mL)</title>
          <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.53" upper_limit="4.99"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.53" upper_limit="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.06" lower_limit="1.75" upper_limit="623.08"/>
                    <measurement group_id="O2" value="102.04" lower_limit="2.21" upper_limit="408.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.24" lower_limit="1.22" upper_limit="536.77"/>
                    <measurement group_id="O2" value="101.51" lower_limit="1.47" upper_limit="402.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Postoperative Pulmonary Complications</title>
        <description>Composite endpoint of clinically relevant pulmonary complications</description>
        <time_frame>Assessed daily, beginning on the first day after surgery, until hospital discharge or death. On average at our institution, most patients are discharged within 7 days so this is the expected time frame for follow up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Anesthesia</title>
            <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Anesthesia</title>
            <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Postoperative Pulmonary Complications</title>
          <description>Composite endpoint of clinically relevant pulmonary complications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prolonged intubation (greater than 48hrs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed extubation (re-intubated within 24hrs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reintubation (greater than 24hrs after extubation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleural effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atelectasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltrate/consolidation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumothorax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brochospasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exacerbation of chronic lung disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxia (PaO2/FiO2 &lt; 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory acidosis (PaCO2 &gt; 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any postoperative pulmonary complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAL Concentration of IL1b (pg/mL)</title>
        <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
        <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Anesthesia</title>
            <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Anesthesia</title>
            <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>BAL Concentration of IL1b (pg/mL)</title>
          <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.06" upper_limit="2.61"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.28" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" lower_limit="0.21" upper_limit="64.77"/>
                    <measurement group_id="O2" value="14.37" lower_limit="1.88" upper_limit="76.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.30" lower_limit="-0.67" upper_limit="59.64"/>
                    <measurement group_id="O2" value="11.00" lower_limit="1.18" upper_limit="66.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAL Concentration of IL6 (pg/mL)</title>
        <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
        <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Anesthesia</title>
            <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Anesthesia</title>
            <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>BAL Concentration of IL6 (pg/mL)</title>
          <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.70" lower_limit="6.77" upper_limit="96.60"/>
                    <measurement group_id="O2" value="31.35" lower_limit="5.27" upper_limit="165.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275.19" lower_limit="6.21" upper_limit="1134.33"/>
                    <measurement group_id="O2" value="297.35" lower_limit="40.59" upper_limit="1277.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.68" lower_limit="-12.41" upper_limit="1046.00"/>
                    <measurement group_id="O2" value="259.32" lower_limit="30.33" upper_limit="1039.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAL Concentration of IL8 (pg/mL)</title>
        <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
        <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Anesthesia</title>
            <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Anesthesia</title>
            <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>BAL Concentration of IL8 (pg/mL)</title>
          <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2008.50" lower_limit="341.25" upper_limit="16444.75"/>
                    <measurement group_id="O2" value="6528.50" lower_limit="625.00" upper_limit="16332.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8019.50" lower_limit="998.25" upper_limit="100438.00"/>
                    <measurement group_id="O2" value="27789.50" lower_limit="4780.50" upper_limit="154087.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4701.00" lower_limit="-290.25" upper_limit="77061.00"/>
                    <measurement group_id="O2" value="16230.00" lower_limit="1399.25" upper_limit="123098.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAL Concentration of MCP1 (pg/mL)</title>
        <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
        <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Anesthesia</title>
            <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Anesthesia</title>
            <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>BAL Concentration of MCP1 (pg/mL)</title>
          <description>Inflammatory mediator found in BAL fluid during lung inflammation</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509.50" lower_limit="249.25" upper_limit="1415.75"/>
                    <measurement group_id="O2" value="977.50" lower_limit="336.50" upper_limit="1225.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496.00" lower_limit="184.25" upper_limit="2153.25"/>
                    <measurement group_id="O2" value="883.50" lower_limit="651.50" upper_limit="4380.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.00" lower_limit="-265.75" upper_limit="869.75"/>
                    <measurement group_id="O2" value="479.50" lower_limit="-104.25" upper_limit="1482.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAL Concentration of sRAGE (pg/mL)</title>
        <description>Biomarker of lung injury (RAGE - receptor for advance glycosylation end products)</description>
        <time_frame>Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Anesthesia</title>
            <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Anesthesia</title>
            <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>BAL Concentration of sRAGE (pg/mL)</title>
          <description>Biomarker of lung injury (RAGE - receptor for advance glycosylation end products)</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.50" lower_limit="44.00" upper_limit="383.00"/>
                    <measurement group_id="O2" value="164" lower_limit="60.75" upper_limit="380.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="597.00" lower_limit="220.50" upper_limit="1195.00"/>
                    <measurement group_id="O2" value="465.00" lower_limit="206.00" upper_limit="2120.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.50" lower_limit="155.25" upper_limit="1063.25"/>
                    <measurement group_id="O2" value="224.50" lower_limit="-69.25" upper_limit="2088.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During hospital length of stay ~7 days</time_frame>
      <desc>During this study, the research team did not record every adverse event. As shown in the table below (as well as the Outcome Measure 2 data), only study related events were recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Anesthesia</title>
          <description>Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.&#xD;
Sevoflurane: Volatile Anesthetic</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Anesthesia</title>
          <description>Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.&#xD;
Propofol: Intravenous Anesthetic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged intubation (greater than 48hrs)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Failed extubation (re-intubated within 24hrs)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Reintubation (greater than 24hrs after extubation)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Infiltrate/consolidation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Brochospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypoxia (PaO2/FiO2 &lt; 300)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis (PaCO2 &gt; 45)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="18"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brian P. O'Gara</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-549-2974</phone>
      <email>bpogara@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

